Therapy with Biologic Agents After Diagnosis of Solid Malignancies: Results from the Corrona Registry

Dimitrios A. Pappas, Sabrina Rebello, Mei Liu, Jennifer Schenfeld, Youfu Li, David H. Collier, Neil A. AccorttThe Journal of Rheumatology 2019 · DOI

Abstract

In real-world practice, nearly one-third of RA patients with a cancer diagnosis were treated with systemic therapy in the immediate visit after malignancy diagnosis and a considerable percentage of malignancy survivors initiated biologic therapy within 3 years. The majority of bDMARD/tsDMARD initiations post-malignancy diagnosis was a TNFi.

Introduction

Managing rheumatoid arthritis (RA) in patients with a recent cancer diagnosis presents a significant clinical challenge. Biologic disease-modifying antirheumatic drugs (bDMARDs) and targeted synthetic drugs (tsDMARDs) are essential for managing RA but carry theoretical risks regarding immune surveillance and cancer recurrence. Because clinical trials often exclude patients with a history of malignancy, real-world data is necessary to guide clinical practice. This study quantifies the frequency and timing of bDMARD/tsDMARD use following a solid malignancy diagnosis.

Methods

The researchers conducted an observational cohort study using data from the Corrona registry (now CorEvitas), a large, independent prospective database of RA patients in the United States. The study cohort included 880 patients diagnosed with a new-onset solid malignancy while enrolled in the registry. The team used Kaplan-Meier methods to calculate the median time to initiation of these drugs post-diagnosis and life-table methods to estimate the proportion of patients starting treatment in 6-month intervals.

Results

Analysis revealed that 30.7% of the 880 patients were receiving a biologic or targeted drug at their first clinical visit following a cancer diagnosis. Prior use was a strong predictor: 41.7% of the cohort had used these therapies before their diagnosis. Among those not on therapy at the first post-cancer visit, 14.8% initiated a biologic within 36 months.

Kaplan-Meier curve showing the probability of no biologic initiation over time following a cancer diagnosis.

The median time to initiate a biologic after diagnosis was approximately 10 years, though the top quartile of patients initiated therapy within just 3 years. TNF inhibitors (TNFi) remained the preferred choice, accounting for 53% of new initiations post-malignancy. Furthermore, 86% of patients who remained on their initial therapy during follow-up were using a TNFi.

Distribution of bDMARD/tsDMARD initiations (left) and persistence on initial therapy (right) during follow-up.

Patients who continued biologic therapy maintained better disease control, with a mean Clinical Disease Activity Index (CDAI) of 8.5, compared to those who delayed or switched therapy (CDAI 15.2–18.3).

Discussion

These findings suggest that clinicians often prioritize joint health and quality of life in RA patients following cancer, particularly when a patient has a successful history with a specific biologic. While the study highlights utilization patterns, it does not directly address safety outcomes regarding cancer recurrence. Future research linking these utilization patterns to long-term oncological outcomes is essential for establishing definitive safety guidelines.

Limitations include potential selection bias (severity of RA vs. cancer risk) and the impact of patients lost to follow-up, which may skew results toward more optimistic outcomes. Approximately 25% of patients who left the study were confirmed to have died, highlighting the potential for survival bias in registry data.

Summary updated

Abstract

In real-world practice, nearly one-third of RA patients with a cancer diagnosis were treated with systemic therapy in the immediate visit after malignancy diagnosis and a considerable percentage of malignancy survivors initiated biologic therapy within 3 years. The majority of bDMARD/tsDMARD initiations post-malignancy diagnosis was a TNFi.
BibTeX
@article{pappas2019therapy,
  author = {Dimitrios A. Pappas and Sabrina Rebello and Mei Liu and Jennifer Schenfeld and Youfu Li and David H. Collier and Neil A. Accortt},
  title = {{Therapy with Biologic Agents After Diagnosis of Solid Malignancies: Results from the Corrona Registry}},
  journal = {The Journal of Rheumatology},
  year = {2019},
  doi = {10.3899/jrheum.171457},
}
Figure